ANDAR

Andina Acquisition Corp. III [ANDAR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ANDAR Stock Summary

In the News

06:00 28 Mar 2024 ANDAR

EMMAC Life Sciences Group (”EMMAC” or the “Group” or the “Company”) Medalchemy receives licence for cultivation of medical cannabis

Spanish EU GMP Facility now has licences to cultivate, extract and manufacture cannabis extract  EMMAC now licensed to cultivate medical cannabis in Portugal and Spain  LONDON, July 28, 2020 (GLOBE NEWSWIRE) -- EMMAC Life Sciences Group, Europe’s largest independent cannabis company, is pleased to announce that Medalchemy, the Group’s Good Manufacturing Practice (“GMP”) certified manufacturing site in Alicante, Spain has secured approval from the Spanish Health Authorities (“AEMPS”) to cultivate medical cannabis. Medalchemy now has fully integrated cannabis supply facilities, with a licence to grow medical cannabis commercially as well as extract and manufacture cannabis extract as an active pharmaceutical ingredient (“API”).EMMAC holds two medical cannabis cultivation licences, one in Spain, at Medalchemy, and the second in Portugal, at its primary cultivation site Terra Verde, which in 2020 has produced and exported c.2 tonnes of medical cannabis flower. EMMAC now holds multiple medical cannabis licences in 4 countries across Europe.Antonio Costanzo, CEO of EMMAC, said: “This latest licence to cultivate medical cannabis at our EU-GMP Facility in Alicante strengthens EMMAC’s position as the leading European independent cannabis company with two culitivation facilities and an alternative point of supply for our business. With full control of our supply chain we are able to ensure a consistent, reliable and high-quality product that our growing customer base can trust. As European legislation quickly evolves to reflect the growing body of medical evidence regarding the benefits of medical cannabis, EMMAC’s integrated business model positions it well to capitalise on the high-growth potential of this valuable market.”Last week, EMMAC announced that the Company signed a non-binding letter of intent related to a business combination with Andina Acquisition Corp. III (NASDAQ: ANDA, ANDAW, and ANDAU) (“Andina”), pursuant to which EMMAC would become a publicly traded company on the NASDAQ Stock Market with EMMAC’s shareholders rolling over all of their equity in EMMAC into the combined public company. As consideration for the transaction, it is anticipated that the current EMMAC shareholders would collectively own a majority of the equity of the combined public company.About EMMAC Life Sciences Group EMMAC Life Sciences Group is Europe’s largest independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it. For more information about EMMAC, please visit https://www.emmac.com/Contact: For scientific enquiries please contact research@emmac.com For general enquiries please contact info@emmac.com or visit www.emmac.comMedia enquiries:Buchanan  Henry Harrison-Topham / Jamie Hooper / Ariadna PeretzTel: +44 (0) 20 7466 5000 emmac@buchanan.uk.comwww.buchanan.uk.com CAUTIONARY STATEMENT All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

11:18 28 Mar 2024 ANDAR

INTERVIEW: European Cannabis Leader EMMAC Gets Lifted Through a SPAC

EMMAC Executive Chairman Lorne Abony By Jarrett Banks EMMAC Life Sciences, Europe’s largest cannabis company, will go public through a merger with Andina Acquistion Corp. III, giving U.S. investors access to the white-hot medical cannabis sector in Europe. EMMAC signed a letter of intent to combine with the special purpose acquisition company, or SPAC, to […]

07:30 28 Mar 2024 ANDAR

European Cannabis Company EMMAC Life Sciences To Go Public On Nasdaq

EMMAC Life Sciences, one of Europe's largest cannabis companies, announced its plans to go public in the U.S.It will list on the Nasdaq exchange through a merger with Andina Acquisition Corp. III (NASDAQ: ANDA) (NASDAQ: ANDAW) (NASDAQ: ANDAU). EMMAC shareholders expect to collectively own a majority stake in the combined public company. EMMAC's Chairman Lorne Abony, CEO Antonio Costanzo, CFO Thomas Ellen, and COO Tom Rooke, will continue to lead the combined entity.Commenting on the news, Luke Weil, Chairman of Andina, told Benzinga that EMMAC is an "extremely attractive investment opportunity due to its leadership position in the large European market, which is driving strong revenue growth with a clear path to profitability."As a Nasdaq-listed company, EMMAC will provide U.S. investors with access to the largest vertically integrated pan-European footprint in the cannabis industry, he explained."EMMAC is the best-positioned company in European cannabis with low cost cultivation, EU-GMP manufacturing and processing, and an extensive import and distribution network in all key European markets," Abony added,The transition to a public company will further fuel the company's growth, support continued research into the medical benefits of cannabis, and solidify its leadership position in Europe."We look forward to partnering with Andina to capitalize on the large market opportunity we see ahead of us as we leverage our low-cost infrastructure, extensive footprint and diversified product portfolio to drive EMMAC's growth," he concluded.Lead image by Ilona Szentivanyi. Copyright: Benzinga.See more from Benzinga * Springbig, GrowFlow Partner Up On Compliance Services * LeafLink Financial Closes 0M In Debt Financing * Vertical Wellness Inks Deals With Tech-Holdings, GenCanna And Kathy Ireland 'To Weather Storm'(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

08:42 28 Mar 2024 ANDAR

Andina Acquisition Corp. III Rights And Warrants: Whether 3rd Time Will Be A Charm By October 31, 2020

Andina Acquisition Corp. III is a LATAM focused SPAC that will hold a special shareholders meeting on July 29, 2020 to extend its liquidation deadline by three months to October.

07:40 28 Mar 2024 ANDAR

Embotelladora Andina SA ADR Series A (AKO.A) Scheduled to Post Quarterly Earnings on Tuesday

Embotelladora Andina SA ADR Series A (NYSE:AKO.A) will be announcing its earnings results after the market closes on Tuesday, April 28th. Investors interested in listening to the company’s conference call can do so using this link. Embotelladora Andina SA ADR Series A (NYSE:AKO.A) last released its quarterly earnings results on Tuesday, February 25th. The company […]

07:30 28 Mar 2024 ANDAR

Embotelladora Andina SA ADR Series A (NYSE:AKO.A) Stock Price Passes Below Two Hundred Day Moving Average of $13.79

Embotelladora Andina SA ADR Series A (NYSE:AKO.A) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $13.79 and traded as low as $10.41. Embotelladora Andina SA ADR Series A shares last traded at $10.50, with a volume of 6,700 shares. […]

07:12 28 Mar 2024 ANDAR

Embotelladora Andina SA ADR Series A (NYSE:AKO.A) Share Price Passes Below 200 Day Moving Average of $14.02

Embotelladora Andina SA ADR Series A (NYSE:AKO.A)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $14.02 and traded as low as $10.96. Embotelladora Andina SA ADR Series A shares last traded at $10.96, with a volume of 1,100 shares changing hands. Separately, […]

11:36 28 Mar 2024 ANDAR

Edited Transcript of AC*.MX earnings conference call or presentation 25-Oct-19 3:00pm GMT

Q3 2019 Arca Continental SAB de CV Earnings Call

06:12 28 Mar 2024 ANDAR

Andina Acquisition Corp. III (NASDAQ:AMCI) and Global Cord Blood (NASDAQ:CO) Head to Head Analysis

Andina Acquisition Corp. III (NASDAQ:AMCI) and Global Cord Blood (NYSE:CO) are both small-cap unclassified companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Profitability This table compares Andina Acquisition Corp. III and Global Cord Blood’s […]

ANDAR Financial details

Company Rating
Neutral
Market Cap
0
Income
-1.18M
Revenue
0
Book val./share
-0.83
Cash/share
3.82
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
7.65
P/C
0.24
P/FCF
-1593.56
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.33
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-
ROE
-
ROC
-0.08%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
0
Shs Float
0
-
-
-
-
Target Price
-
52W Range
0.825-0.9131
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
-
Volume
512.2K
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.905
Change
-

ANDAR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric History 2017-12-312018-12-312019-12-31 2020-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000
Net income per share
000.510
Operating cash flow per share
00-0.12-0.07
Free cash flow per share
00-0.12-0.07
Cash per share
000.13.99
Book value per share
0032.061.45
Tangible book value per share
00.0132.061.45
Share holders equity per share
0032.061.45
Interest debt per share
00.0100
Market cap
134.78M134.78M34.98M36.74M
Enterprise value
134.8M134.89M34.63M36.54M
P/E ratio
-317.88K-9.12K19.850
Price to sales ratio
0000
POCF ratio
-21.37K-17.7K-87.65-144.45
PFCF ratio
-21.37K-17.7K-87.65-144.45
P/B Ratio
12.51K-33.72K0.327.35
PTB ratio
12.51K-33.72K0.327.35
EV to sales
0000
Enterprise value over EBITDA
-317.93K-9.13K19.65-32.06
EV to operating cash flow
-21.37K-17.72K-86.77-143.67
EV to free cash flow
-21.37K-17.72K-86.77-143.67
Earnings yield
000.050
Free cash flow yield
00-0.01-0.01
Debt to equity
2.06-26.6400
Debt to assets
0.310.3400
Net debt to EBITDA
-52.23-7.21-0.20.17
Current ratio
1.430.9863.010
Interest coverage
0000
Income quality
14.880.52-0.230
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
0000
Capex to revenue
0000
Capex to depreciation
0000
Stock based compensation to revenue
0000
Graham number
0019.210
ROIC
-0.01-0.1400
Return on tangible assets
-0.01-0.050.020
Graham Net
0-0.010.11.45
Working capital
10.78K-4K354.88K198.19K
Tangible asset value
46.61K152.28K110.5M5M
Net current asset value
10.78K-4K354.88K-8.55M
Invested capital
2.06-26.6400
Average receivables
0000
Average payables
06.5K7.9K2.86K
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
-0.043.70.020
Capex per share
0000

Quarterly Fundamentals Overview

Last date of statement is 2021-06-30 for Q2

Metric History 2019-06-302019-12-312020-06-302020-12-31 2021-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
0.170.11-0.220-0.22
Operating cash flow per share
-0.02-0.01-0.03-0.01-0.04
Free cash flow per share
-0.02-0.01-0.03-0.01-0.04
Cash per share
0.130.10.053.863.82
Book value per share
31.0631.3130.891.4-0.83
Tangible book value per share
31.0631.3130.891.42.97
Share holders equity per share
31.0631.3130.891.4-0.83
Interest debt per share
00000
Market cap
34.98M35.83M36.55M37.98M36.73M
Enterprise value
34.54M35.47M36.38M37.78M36.67M
P/E ratio
14.9322.94-11.70-11.62
Price to sales ratio
00000
POCF ratio
-423.15-815.35-405.87-1.63K-264.19
PFCF ratio
-423.15-815.35-405.87-1.63K-264.19
P/B Ratio
0.320.320.337.6-12.46
PTB ratio
0.320.320.337.6-12.46
EV to sales
00000
Enterprise value over EBITDA
58.9690.86-46.59-33.14-46.41
EV to operating cash flow
-417.78-807.33-404-1.62K-263.77
EV to free cash flow
-417.78-807.33-404-1.62K-263.77
Earnings yield
0.020.01-0.020-0.02
Free cash flow yield
00000
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
-0.76-0.90.220.170.07
Current ratio
73.3863.010.2800.04
Interest coverage
00000
Income quality
-0.14-0.110.1200.18
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
10.778.8312.3402.03
ROIC
00-0.0100.23
Return on tangible assets
0.010-0.010-0.06
Graham Net
0.120.1-0.161.42.97
Working capital
533.68K354.88K-523.58K198.19K-2.08M
Tangible asset value
109.64M110.5M110.06M5M10.59M
Net current asset value
533.68K354.88K-523.58K-8.55M-2.95M
Invested capital
00000
Average receivables
00000
Average payables
8.72K6.55K2.86K00
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0.010-0.0100.27
Capex per share
00000

ANDAR Frequently Asked Questions

What is Andina Acquisition Corp. III stock symbol ?

Andina Acquisition Corp. III is a US stock and trading under the symbol ANDAR

What is Andina Acquisition Corp. III stock quote today ?

Andina Acquisition Corp. III stock price is $0.905 today.

Is Andina Acquisition Corp. III stock public?

Yes, Andina Acquisition Corp. III is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Check Those
Similar Market Cap